Severity

A subset of Member States and areas monitors severe disease related to influenza virus infection by surveillance of 1) hospitalized laboratory-confirmed influenza cases in ICUs (12 Member States or areas), or other wards (8 Member States or areas), or 2) severe acute respiratory infections (SARI; 17 Member States or areas).

1.1) Hospitalized laboratory-confirmed influenza cases – ICUs

Among laboratory-confirmed influenza cases reported in ICUs for week 44/2018 (n = 7), there were 6 with influenza type A and 1 with influenza type B virus infection.

Since week 40/2018, 15 cases (88%) have been reported with influenza type A viruses and 2 (11%) with influenza type B viruses. Of 8 subtyped influenza A viruses, all were A(H1N1)pdm09. No influenza B viruses were ascribed to a lineage.

1.2) Hospitalized laboratory-confirmed influenza cases – other wards

Among laboratory-confirmed influenza cases reported in wards other than ICUs for week 44/2018 (n = 3), all were infected with influenza type A viruses.

Since week 40/2018, 16 cases (80%) have been reported with influenza type A viruses and 4 (20%) with influenza type B viruses. Of 5 subtyped influenza A viruses, 3 were A(H1N1)pdm09 and 2 A(H3N2). No influenza B viruses were ascribed to a lineage.

 

2. SARI surveillance

For week 44/2018, 815 SARI cases were reported by 13 countries. Of 131 specimens tested for influenza viruses, none were positive.

Of 3 285 SARI cases reported since week 40/2018, 3 281 had age reported and, of these, 63.2% were 0–4 years old and 19.4% were 15–64 years old. Since week 40/2018, only 1 SARI case has tested positive for influenza virus and it was subtype A(H1N1)pdm09.

 

Mortality monitoring

For week 44/2018, the EuroMOMO project received data from 18 EU/EEA Member States and areas that were included in pooled analyses. Overall, the pooled estimates of all-cause mortality showed expected levels for this time of year in the participating countries.